{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:15:13Z","timestamp":1788797713001,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET\/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data. For [68Ga]Ga-PSMA-11, the radiochemical yield (RCY) using a low starting activity (L, average activity of 596.55 \u00b1 37.97 MBq) was of 80.98 \u00b1 0.05%, while using a high one (H, average activity of 1436.27 \u00b1 68.68 MBq), the RCY was 71.48 \u00b1 0.04%. Thus, increased starting activities of [68Ga]-chloride negatively influenced the RCY. A similar scenario occurred for [18F]PSMA-1007. The rate of detection of PCa lesions by Positron Emission Tomography\/Computed Tomography (PET\/CT) was similar for both radioligands, while their distribution in normal organs significantly differed. Furthermore, similar patterns of biodistribution were found among [18F]PSMA-1007, [68Ga]Ga-PSMA-11, and [177Lu]Lu-PSMA-617, the most used agent for RLT. Moreover, the analysis of economical aspects for each single batch of production corrected for the number of allowed PET\/CT examinations suggested major advantages of [18F]PSMA-1007 compared with [68Ga]Ga-PSMA-11. Data from this study should support the proper choice in the selection of the PSMA PET radioligand to use on the basis of the cases to study.<\/jats:p>","DOI":"10.3390\/molecules27123862","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:25:11Z","timestamp":1655443511000},"page":"3862","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET\/CT Applications in Patients with Prostate Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-9909","authenticated-orcid":false,"given":"Costantina","family":"Maisto","sequence":"first","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Aurilio","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, ASL 1 \u201cOspedale del Mare\u201d Hospital, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morisco","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"de Marino","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Josefa","family":"Buonanno Recchimuzzo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Carideo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Gennaro","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureliana","family":"Esposito","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gaballo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pirozzi Palmese","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Porfidia","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Raddi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Squame","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Lastoria","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80127 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/tau.2017.12.30","article-title":"Men with a susceptibility to prostate cancer and the role of genetic based screening","volume":"7","author":"Eeles","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_2","first-page":"178","article-title":"A comparison of the diagnostic performance of 18F-PSMA-1007 and 68GA-PSMA-11 in the same patients presenting with early biochemical recurrence","volume":"24","author":"Lengana","year":"2021","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","article-title":"44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617","volume":"7","author":"Umbricht","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"177Lu-PSMA Radioligand Therapy for Prostate Cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41181-021-00150-z","article-title":"On site production of [18F]PSMA-1007 using different [18F]fluoride activities: Practical, technical and economical impact","volume":"6","author":"Maisto","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kaewput, C., and Vinjamuri, S. (2022). Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102738"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2967\/jnumed.115.171249","article-title":"Comprehensive Quality Control of the ITG 68Ge\/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging","volume":"57","author":"Schoendorf","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jussing, E., Milton, S., Sam\u00e9n, E., Moein, M.M., Bylund, L., Axelsson, R., Siikanen, J., and Tran, T.A. (2021). Clinically Applicable Cyclotron-Produced Gallium-68 Gives High-Yield Radiolabeling of DOTA-Based Tracers. Biomolecules, 11.","DOI":"10.3390\/biom11081118"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.apradiso.2021.109825","article-title":"Cyclotron-produced 68Ga from enriched 68Zn foils","volume":"176","author":"Siikanen","year":"2021","journal-title":"Appl. Radiat. Isot."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2019.07.005","article-title":"Rapid and automated production of [68Ga]gallium chloride and [68Ga]Ga-DOTA-TATE on a medical cyclotron","volume":"74\u201375","author":"Tieu","year":"2019","journal-title":"Nucl. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-020-00114-9","article-title":"Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE","volume":"6","author":"Thisgaard","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nucmedbio.2017.07.006","article-title":"Continuation of comprehensive quality control of the itG 68Ge\/68Ga generator and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical research studies","volume":"53","author":"Kelly","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nucmedbio.2021.12.005","article-title":"Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals","volume":"106\u2013107","author":"Piron","year":"2022","journal-title":"Nucl. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.crad.2020.06.031","article-title":"Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: Normal patterns, pearls, and pitfalls","volume":"75","author":"Foley","year":"2020","journal-title":"Clin. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non\u2013Tumor-Related Uptake and Tumor Positivity","volume":"62","author":"Kroenke","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography","volume":"76","year":"2013","journal-title":"Appl. Radiat. Isot."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hoffmann, M.A., von Eyben, F.E., Fischer, N., Rosar, F., M\u00fcller-H\u00fcbenthal, J., Buchholz, H.G., Wieler, H.J., and Schreckenberger, M. (2022). Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET\/CT in Restaging of Prostate Cancer Patients with PSA Relapse. Cancers, 14.","DOI":"10.3390\/cancers14061479"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","article-title":"Physics of pure and non-pure positron emitters for PET: A review and a discussion","volume":"3","author":"Conti","year":"2016","journal-title":"EJNMMI Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3862\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:32:50Z","timestamp":1760139170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["molecules27123862"],"URL":"https:\/\/doi.org\/10.3390\/molecules27123862","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}